Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: (no name provided) who wrote (465)	12/28/1997 12:25:00 PM
From: Brander	Read Replies (1) \| Respond to of 834

Kafka; "What exactly is so bad about in-licensing drugs?" Nothing, as long as it is profitable for the company. Your are correct, this is a common practice, and has worked very well for other companies. ""Development" is obviously a relative term." True. I don't think TXB lied. I am not even saying that they overtly mislead anyone. I pointed this out because, in light of Mr Wexler's claims, it might appear to the misinformed investor that TXB was trying to pull the wool over their eyes. I was also giving him the benefit of the doubt on this point, in hopes that he will respond to my requests that he provide us with evidence backing his serious charge that TXB fudged the results of their clinical trials on Novastan. My bet is that he can't. In fact, I very strongly believe he can't. The scientific investigators involved are very reputable and they would not allow it. I also strongly doubt that TXB would be involved in that type of activity. If it were true, it would have to come to light 1st or 2nd Q 1998, when the FDA decides, and TXB would be delisted.....I doubt very much that TXB would do that. Brad